From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here we give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here
| ISBN: | 9783642136627 |
| Publication date: | 1st October 2010 |
| Author: | Christian Rommel, Bart Vanhaesebroeck, P K Vogt |
| Publisher: | Springer an imprint of Springer Berlin Heidelberg |
| Format: | Hardback |
| Pagination: | 310 pages |
| Series: | Current Topics in Microbiology and Immunology |
| Genres: |
Oncology Medical research Physiology |